Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06384248Phase 1Not Yet Recruiting

Phase II Clinical Study of LTC004 in Patients With Advanced Sarcoma

Role: lead

NCT06384235Phase 1Not Yet Recruiting

Phase II Clinical Study of LTC004 in Patients With mCRC

Role: lead

NCT06277804Phase 1Not Yet Recruiting

A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor

Role: lead

NCT05666635Phase 1Unknown

Study of LTC004 in Subjects With Advanced Malignant Tumors

Role: lead

All 4 trials loaded